faropenem medoxomil

Faropenem medoxomil is an orally active ester prodrug of the beta-lactam antibiotic faropenem, belonging to the penem class. It is designed to improve oral bioavailability and systemic concentrations compared to its parent compound. After administration, it is hydrolyzed in vivo to release active faropenem. Faropenem acts as a broad-spectrum antibacterial agent with activity against many gram-positive and gram-negative aerobes and anaerobes. Its mechanism of action involves inhibition of bacterial cell wall synthesis by binding to and inhibiting penicillin-binding proteins (PBPs), thereby blocking cross-linking of peptidoglycan chains essential for cell wall integrity. Faropenem exhibits high resistance to beta-lactamase degradation and improved chemical stability over other carbapenems, with reduced central nervous system effects. It has been developed primarily for community-acquired infections such as acute bacterial sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis, uncomplicated skin and skin structure infections, among others[1][2][3][4][5][6].

Brand names

Farom

Other names

faropenem daloxatefaropenem medoxilfropenem daloxate